A5084657878- Veterinary Oncology Research
- Cancer Research and Treatments
- Sarcoma Diagnosis and Treatment
- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- Cell Adhesion Molecules Research
- Chemokine receptors and signaling
- Monoclonal and Polyclonal Antibodies Research
- Angiogenesis and VEGF in Cancer
- Nanoplatforms for cancer theranostics
- Extracellular vesicles in disease
- Photoacoustic and Ultrasonic Imaging
- vaccines and immunoinformatics approaches
- Cardiovascular Disease and Adiposity
University of Illinois Urbana-Champaign
2019-2024
<p>Immunohistochemical analysis of the excised lesion from patients 008 and 014 reveals morphological changes indicative granulomatous inflammation.</p>
<p>CD3+ T lymphocytes and IBA1+ macrophage infiltration prior after administration of JEN-101.</p>
<div>Abstract<p>Melanoma is an aggressive cancer in dogs involving skin and mucosa similar to humans. Anchored immunotherapeutics offer a novel approach increase intratumoral retention of therapeutic payloads while decreasing systemic exposure, this strategy can be critically evaluated through comparative oncology approach. JEN-101 anchored canine IL-12 tethered aluminum hydroxide administered by local injection. A phase I study was conducted determine the tolerability, activity,...
<p>Circulating IL-10 response to treatment with JEN-101.</p>
<p>Safety hematological and biochemical profile of JEN-101 treatment.</p>
<p>Patient 006 treated with JEN-101 and a CTLA-4 inhibitor.</p>
<p>NanoString RNA cell type profiling and pathway scores of primary tumor lesions.</p>
<p>Circulating c-IL-12-ABP levels in patient 010.</p>
<p>Dose/Tumor Volume ratio and correlation with best response.</p>
<p>Characterization of anti-drug antibody (ADA) responses in dogs at day 63 (dose 4).</p>
<p>Supplemental Data File containing raw data generated in this study.</p>
Cytokine therapies such as IL2 and IL12 suffer from impractically small therapeutic windows driven by their on-target, off-tumor activity, limiting clinical potential despite potent antitumor effects. We previously engineered cytokines that bind anchor to tumor collagen following intratumoral injection, sought test safety biomarker activity in spontaneous canine soft-tissue sarcomas (STS).Collagen-binding were canine-ized minimize immunogenicity used a rapid dose-escalation study healthy...
Cytokines IL2 and IL12 exhibit potent anticancer activity but suffer a narrow therapeutic window due to off-tumor immune cell activation. Engineering cytokines with the ability bind associate tumor collagen after intratumoral injection potentiated response without toxicity in mice was previously safe pet dogs sarcoma. Here, we sought test efficacy of this approach advanced melanoma.
Abstract Background: Malignant melanoma is the most common form of oral cancer in canines with a median survival 3 months for dogs stage III or IV disease. Currently, there are limited effective systemic treatment options these patients advanced We have developed an anchored immunotherapy approach which canine interleukin-12 stably linked to aluminum hydroxide (cANK-101). The IL-12 forms stable, functional depot and expected increase therapeutic responses toxicity. report preliminary results...
ABSTRACT The clinical use of interleukin-2 and -12 cytokines against cancer is limited by their narrow therapeutic windows due to on-target, off-tumor activation immune cells when delivered systemically. Engineering IL-2 IL-12 bind extracellular matrix collagen allows these be retained within tumors after intralesional injection, overcoming safety challenges. While this approach has potentiated responses in syngeneic mouse without toxicity, the complex tumor-immune interactions human cancers...
<p>Supplemental Data S1. Supplemental File containing raw data generated in this study.</p>
<p>Supplemental Figure S1. Local RT causes transient lymphodepletion in murine melanomas.</p>
<p>Supplemental Data S1. Supplemental File containing raw data generated in this study.</p>